Data Insights

Ibrutinib by AbbVie for Follicular Lymphoma: Likelihood of Approval

Ibrutinib is under clinical development by AbbVie and currently in Phase III for Follicular Lymphoma. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Ibrutinib in Follicular Lymphoma

Data Insights

Ibrutinib by AbbVie for Primary CNS Lymphoma: Likelihood of Approval

Ibrutinib is under clinical development by AbbVie and currently in Phase II for Primary CNS Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ibrutinib in Primary CNS Lymphoma

Data Insights

Ibrutinib by AbbVie for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval

Ibrutinib is under clinical development by AbbVie and currently in Phase III for Splenic Marginal Zone B-Cell Lymphoma. According to...

Data Insights

Ibrutinib by AbbVie for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval

Ibrutinib is under clinical development by AbbVie and currently in Phase III for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid...

Data Insights

Ibrutinib by AbbVie for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval

Ibrutinib is under clinical development by AbbVie and currently in Phase III for Nodal Marginal Zone B-Cell Lymphoma. According to...

Data Insights

Ibrutinib by AbbVie for Primary CNS Lymphoma: Likelihood of Approval

Ibrutinib is under clinical development by AbbVie and currently in Phase II for Primary CNS Lymphoma. According to GlobalData, Phase...

Data Insights

Ibrutinib by AbbVie for Renal Cell Carcinoma: Likelihood of Approval

Ibrutinib is under clinical development by AbbVie and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase...